Exec-Edge
1 min read
In This Article:
Download the Complete Report Here
By Rayk Riechmann
Aurora Cannabis (Nasdaq: ACB) continued to fly high as it closed out fiscal 2025, with net revenue topping street estimates and prospects looking brighter as it progresses through the new year.
On the back of a strong international expansion strategy, Aurora Cannabis reported a record topline of C$343 million (+27% y/y) for fiscal 2025. The Canadian medical cannabis leader stands out with an outstanding profitability profile and strong foothold in international markets.
For FY25, high-margin international medical cannabis sales contributed significantly to a record adjusted EBITDA of C$49.7 million. ACB is also taking steps to enter new emerging markets such as Switzerland, Austria, and New Zealand, offering clear visibility into future growth.
Following the quarterly read, shares have dropped more-than 35%, offering a potential entry opportunity for patient investors. Despite a weaker guidance for 1Q FY26, we believe that growth will return in the mid-term future as regulatory issues ease and ACB moves into new markets.
ACB is a leading global cannabis name that trades at a significant discount to peers – despite a bulletproof balance sheet and impressive growth opportunities globally.
Click the link below to find a detailed quarterly update report on our favorite plug from Canada.
Download the Complete Report Here
Contact:
